mirtazapine / Generic mfg. - LARVOL DELTA

A Neurotoxicity Mimic: Progressive Multifocal Leukoencephalopathy Following BCMA-Directed CART and Bispecific Therapies (TCT-ASTCT-CIBMTR 2026) - "He received cilta-cel as 5th line therapy following bridging with talquetamab...He was treated with high-dose IVIG, mirtazapine, and pembrolizumab... These cases highlight a devastating complication of BCMA-directed therapy. Increasing use of BCMA- targeted platforms warrants collaboration to define incidence, risk factors, and develop strategies for prevention and treatment. Progressive multifocal leukoencephalopathy is rare, but catastrophic complication of BCMA-directed immune therapies."

CNS Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Rare Diseases • CD4

Peripheral edema associated with the combination of mirtazapine and escitalopram. (PubMed, Med J Armed Forces India) - "This report discusses a rare case of peripheral edema in a young female patient, emphasizing the importance of recognizing rare adverse reactions in diverse populations. Enhanced awareness and continued research could lead to better understanding and management of this uncommon yet notable side effect of escitalopram."

Journal • CNS Disorders • Depression • General Anxiety Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry

Prediction of 12-Week Remission in Patients With Depressive Disorder Using Reasoning-Based Large Language Models: Model Development and Validation Study. (PubMed, JMIR Ment Health) - "We analyzed data from 390 patients in the MAKE Biomarker discovery study who were undergoing first-step antidepressant monotherapy with 12 different medications, including escitalopram, paroxetine, sertraline, duloxetine, venlafaxine, desvenlafaxine, milnacipran, mirtazapine, bupropion, vortioxetine, tianeptine, and trazodone, after excluding those with uncommon medications (n=9) or missing biomarker data (n=32). Clinical evaluation by psychiatrists showed favorable mean ratings for correctness (4.3, SD 0.7), consistency (4.2, SD 0.8), specificity (4.2, SD 0.7), helpfulness (4.2, SD 1.0), and human likeness (3.6, SD 1.7) on 5-point scales. These findings demonstrate that reasoning-based LLMs, particularly when enhanced with research-informed prompting, show promise for predicting antidepressant response and could serve as interpretable adjunctive tools in depressive disorder treatment planning, although prospective validation in real-world clinical settings remains..."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Progressive multifocal leukoencephalopathy associated with elranatamab therapy in relapsed/refractory multiple myeloma. (PubMed, J Oncol Pharm Pract) - "Despite treatment with intravenous immunoglobulin, mirtazapine, and compassionate-use nivolumab, her neurological status progressively worsened, necessitating intubation and intensive care management.DiscussionThis case suggests a probable association between elranatamab therapy and JC virus reactivation leading to PML. Early neuroimaging and cerebrospinal fluid JC virus testing, combined with proactive immunoglobulin replacement and systematic pharmacovigilance, are essential for timely diagnosis and improved outcomes. Overall, this case highlights the need for early JC virus monitoring and awareness of delayed neuroinfectious complications associated with BCMA-targeted immunotherapies."

Journal • CNS Disorders • Critical care • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology • Rare Diseases

Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov) - P2 | N=98 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial primary completion date • Anorexia • CNS Disorders • Insomnia • Oncology • Sleep Disorder

Antidepressants and Risk of Mortality in People with Depressive Disorder and Co-occurring type 2 Diabetes Mellitus: a 20-year Population-based Cohort Study. (PubMed, Psychother Psychosom) - "Depression patients with comorbid type-2 diabetes with exposure to several antidepressant is at decreased mortality risk. Further research is warranted to confirm our findings and clarify the mortality-reducing mechanisms of antidepressant in this vulnerable population."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Depression • Diabetes • Metabolic Disorders • Mood Disorders • Psychiatry • Type 2 Diabetes Mellitus

Mirtazapine for Acute and Chronic Post Mastectomy Pain (clinicaltrials.gov) - P1 | N=62 | Completed | Sponsor: Assiut University | Active, not recruiting ➔ Completed | Trial completion date: Dec 2027 ➔ Dec 2025 | Trial primary completion date: Jul 2027 ➔ Dec 2025

Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Pain • Solid Tumor

Analysis of drug-drug interactions between psychiatric drugs in spontaneous adverse drug reaction reports from EudraVigilance. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Mirtazapine-quetiapine (26.3%, 10/48) was the interacting drug pair most commonly associated with tachycardia and QT prolongation. Checks for interactions and tight monitoring after initiating drug therapy can help to avoid serious DDI. Special attention should be paid to older patients taking more than one QT-interval prolonging drug."

Adverse drug reaction • Journal • Anesthesia • Cardiovascular • CNS Disorders • Epilepsy • Psychiatry

Effect of Mirtazapine on Energy Intake in Patients with Anorexia Associated with NSCLC (IASLC-WCLC 2022) - "Patients with cancer-related anorexia can improve nutritional intake with the addition of mirtazapine, which promotes energy consumption reflected in diverse macronutrients."

Clinical • Anorexia • Cachexia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial. (PubMed, JAMA Oncol) - P=N/A | "The addition of mirtazapine in the treatment of patients with advanced NSCLC and anorexia may help these patients achieve their energy requirements and improve health-related quality of life, specifically emotional and cognitive functioning. ClinicalTrials.gov Identifier: NCT04748523."

Clinical • Journal • Anorexia • Cachexia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Sarcopenia • Solid Tumor

Treating the Pain After the Cure: Therapeutic Approaches for Post-ECT Headache-A Systematic Review. (PubMed, J ECT) - "Treatments evaluated included sumatriptan, nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, propranolol, topiramate, valproic acid, mirtazapine, dihydroergotamine, topical salicylates, cryotherapy, and percutaneous electrical nerve stimulation. However, clinical phenotyping and a stepwise therapeutic approach may improve symptom control. This review provides a comprehensive summary of current options and offers guidance for individualized management of post-ECT headache."

Journal • CNS Disorders • Migraine • Musculoskeletal Pain • Pain

Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. (PubMed, Mov Disord) - "Current evidence from RCTs with at least 1 month of follow-up is insufficient to confidently support the efficacy of available medical treatments for ET. There is a need for longer, higher-quality clinical trials to improve treatment recommendations and guide decision-making for clinicians and patients with ET."

Journal • Review • CNS Disorders • Essential Tremor • Movement Disorders • Parkinson's Disease

Nasal powder formulation employing microenvironmental pH-modifier for rapid absorption of mirtazapine. (PubMed, Pharm Sci Adv) - "NP/MRZ-E (0.3 ​mg-MRZ/kg, i.n.) showed T max of <5 ​min with BA of 93%, and this result might be due to rapid dissolution/permeation in nasal mucosa and avoidance of the hepatic first-pass effect. In conclusion, NP employing a microenvironmental pH-modifier would be a promising dosage form of MRZ to offer rapid nasal absorption."

Journal • CNS Disorders

Dose-dependent pharmacological mechanisms within the Neuroscience-based Nomenclature: a new concept to facilitate neuroscience-based prescribing. (PubMed, Lancet Psychiatry) - "Using the Neuroscience-based Nomenclature (NbN) framework, which classifies drugs by pharmacology and modes of action, we identified ten agents demonstrating DDDP in a comprehensive expert-based consensus process: amisulpride, amitriptyline, aripiprazole, brexpiprazole, cariprazine, doxepin, mirtazapine, quetiapine, risperidone, and trazodone...Understanding these differences supports more rational prescribing (eg, increasing dopamine partial agonist doses beyond the optimal range might reduce efficacy). DDDP, within the NbN framework, offers a neuroscience-based approach to more precise psychopharmacology."

Journal • Review • NBN

Antidepressant use in German adolescents with a first recorded diagnosis of depression: a retrospective cohort study. (PubMed, Eur Child Adolesc Psychiatry) - "In German adolescents with depression, older age, greater symptom severity, and certain psychiatric comorbidities were strongly linked to antidepressant use. SSRIs were most frequently prescribed, particularly fluoxetine, with sertraline and escitalopram also common. St. John's Wort and mirtazapine were used less often. These findings underline the importance of considering age, severity, and coexisting psychiatric disorders when managing adolescent depression."

Journal • Retrospective data • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Social Anxiety Disorder

Antidepressants and the risk of hyponatremia: A multi-institutional cohort study using observational medical outcomes partnership-Common Data Model. (PubMed, Br J Clin Pharmacol) - "Close monitoring of serum sodium levels is essential for SSRI users, especially those aged ≥60 years."

Journal • Licensing / partnership • Cardiovascular • CNS Disorders • Depression • Heart Failure • Psychiatry

TNA-LBP: Treating Negative Affect in Low Back Pain Patients (clinicaltrials.gov) - P2/3 | N=308 | Completed | Sponsor: Ajay Wasan, MD, Msc | Active, not recruiting ➔ Completed | Trial completion date: Apr 2026 ➔ Dec 2025

Trial completion • Trial completion date • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Comparative acceptability of first-line antidepressants among older adults using filled prescription sequences: A nationwide cohort study. (PubMed, J Affect Disord) - "This large real-world study suggests differences in the acceptability of first-line antidepressants between older and younger patients. Although escitalopram ranked first regardless of age, alpha-2 blockers (mianserin and mirtazapine) emerged as acceptable options in older patients only."

Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

MDD: Neurobiological and Genomic Predictors of Relapse in Depression (clinicaltrials.gov) - P=N/A | N=204 | Recruiting | Sponsor: Mehmet Kemal Arikan

New trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Comparative effects of antidepressants on cocaine-induced hyperthermia in rats: a preclinical study. (PubMed, Neurosci Lett) - "Mirtazapine may be a safer antidepressant option for managing depression in cocaine users because of its capacity to suppress hyperthermia without enhancing monoamine reuptake inhibition. Notably, caution should be exercised when prescribing monoamine oxidase inhibitors and SNRIs to this population. However, further clinical studies are required to validate these findings."

Journal • Preclinical • CNS Disorders • Depression • Psychiatry

Depression Aggravates Immune-Mediated Hepatitis Through NLRP3 Overactivation Induced by Intestinal Microbiota. (PubMed, CNS Neurosci Ther) - "Depression aggravates immune-mediated hepatitis through disruption of intestinal barrier integrity and overactivation of hepatic NLRP3 inflammasome. Gut-derived L. formosensis could translocate to the liver and induce liver injury in mice. This study provides the necessity of screening for depression in patients with AIH."

Journal • Autoimmune Hepatitis • CNS Disorders • Depression • Fibrosis • Hepatology • Immunology • Inflammation • Liver Failure • Major Depressive Disorder • Psychiatry • Transplantation • NLRP3

Severe Alcohol Use Disorder in a Patient Who Is Deaf, Mute, and Having Limited Literacy: A Case Report and Review of Disability-Linked Substance Use Vulnerabilities. (PubMed, Cureus) - "Management included a lorazepam taper, naltrexone initiation, mirtazapine for mood symptoms, and osteopathic manipulative treatment for somatic complaints. This case highlights the need for culturally and linguistically adapted withdrawal tools, early interpreter involvement, and disability-informed addiction treatment. To our knowledge, this is among the first reports describing detoxification of a deaf, mute, and illiterate patient with severe AUD, underscoring the urgency of inclusive clinical protocols."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Otorhinolaryngology • Psychiatry

Do we need to improve pharmacological approaches to treat insomnia in patients with opioid use disorder? (PubMed, Expert Opin Pharmacother) - "A selection of medications, including trazodone and mirtazapine, have been studied as treatments for insomnia among individuals with OUD. Improved pharmacotherapies targeting this pathology are critical not only for enhancing quality of life but also the success of OUD treatment outcomes. Large, rigorous clinical trials are sorely needed to improve sleep medication prescribing guidelines in this population."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Insomnia • Sleep Disorder • Substance Abuse

Effects of Mirtazapine on Appetite in Advanced Cancer Patients (clinicaltrials.gov) - P2 | N=98 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial primary completion date: Dec 2027 ➔ Dec 2025

Trial primary completion date • Anorexia • CNS Disorders • Insomnia • Oncology • Sleep Disorder

Mirtazapine or ondansetron for hyperemesis gravidarum. A randomized placebo-controlled trial. (PubMed, Am J Obstet Gynecol) - P2 | "The trial showed reduced PUQE-24 score in the mirtazapine group compared with the placebo group among pregnant people with hyperemesis gravidarum. Ondansetron resulted in a smaller reduction in PUQE-24 score that did not reach statistical significance."

Journal • Rare Diseases